Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Deucravacitinib

First Posted Date: 2024-08-22

Last Posted Date: 2025-07-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 52

Registration Number: NCT06566768

Locations: 🇬🇧
Local Institution - 0001, Nottingham, Nottinghamshire, United Kingdom

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Nivolumab
Drug: Relatlimab
Drug: Carboplatin
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2024-08-20

Last Posted Date: 2025-06-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1000

Registration Number: NCT06561386

Locations: 🇺🇸
Local Institution - 0368, Tucson, Arizona, United States
🇺🇸
Local Institution - 0112, Los Angeles, California, United States
🇺🇸
Local Institution - 0304, Sacramento, California, United States

and more 269 locations

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Recruiting

Conditions: Obstructive Hypertrophic Cardiomyopathy

Interventions: Drug: Mavacamten

First Posted Date: 2024-08-13

Last Posted Date: 2024-11-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 118

Registration Number: NCT06551129

Locations: 🇺🇸
Analysis Group Inc., Boston, Massachusetts, United States

A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

Active, not recruiting

Conditions: Hypertrophic Cardiomyopathy

Interventions: Drug: Mavacamten

First Posted Date: 2024-08-12

Last Posted Date: 2025-02-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 685

Registration Number: NCT06549608

Locations: 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BMS-986484
Biological: Nivolumab

First Posted Date: 2024-08-09

Last Posted Date: 2025-03-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 134

Registration Number: NCT06544655

Locations: 🇦🇺
St Vincent's Hospital, Darlinghurst, New South Wales, Australia
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸
Local Institution - 0003, Tucson, Arizona, United States

and more 8 locations

A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Deucravacitinib

First Posted Date: 2024-07-22

Last Posted Date: 2025-02-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 150

Registration Number: NCT06512337

Locations: 🇨🇳
Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China

Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France

Recruiting

Conditions: Esophageal Adenocarcinoma (EAC)
Gastro-esophageal Junction Adenocarcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
Gastric Adenocarcinoma

Interventions: Drug: nivolumab + chemotherapy

First Posted Date: 2024-07-17

Last Posted Date: 2024-12-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 500

Registration Number: NCT06504615

Locations: 🇫🇷
KAPPA SANTE Institution, Paris, France
🇫🇷
Kappa Santé, Paris, France

Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

Completed

Conditions: Esophageal Cancer
Gastroesophageal Junction Cancer

Interventions: Drug: Nivolumab

First Posted Date: 2024-07-12

Last Posted Date: 2025-05-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 64

Registration Number: NCT06499298

Locations: 🇨🇳
Local Institution - 0001, Shanghai, China

A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Repotrectinib
Drug: Voriconazole
Drug: Quinidine

First Posted Date: 2024-07-10

Last Posted Date: 2025-03-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT06493409

Locations: 🇺🇸
Fortrea - Daytona Beach, Daytona Beach, Florida, United States

A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Nivolumab + ipilimumab

First Posted Date: 2024-07-05

Last Posted Date: 2024-07-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 400

Registration Number: NCT06487156

Locations: 🇮🇹
Istituto Nazionale Tumori - IRCCS Fondazione G.Pascale, Napoli, Italy

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy